author-photo

Yining Ye

19

Papers

386

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions

2019 Hepatobiliary surgery and nutrition
Show All
- Source
- Cite
- Save
Citations (14)
Abstract 2206: Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
832TiPInfigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Activity of the FGFR1–3 inhibitor infigratinib in patients with upper tract urothelial carcinoma and urothelial carcinoma of the bladder: Latest efficacy findings and comprehensive genomic profiling/cell-free DNA data

2019 European Urology Supplements
Show All
- Source
- Cite
- Save
Citations (0)
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

2019 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (10)
Abstract P1-13-05: Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract S5-02: Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
Demonstrating Biosimilarity via Equivalence in Clinical Trials

2012 Statistics in Biopharmaceutical Research
- Yining Ye
- Bin. Yao
Show All
- Source
- Cite
- Save
Citations (2)